Understanding and interpreting serum protein electrophoresis
Theodore X. O’Connell
Serum serum protein electrophoresis is a laboratory examination that commonly is used to identify patients with multiple myeloma and other disorders of protein. Many subspecialists include serum protein electrophoresis screening in the initial evaluation for numerous clinical conditions. Sometimes, however, the results of this examination can be confusing or difficult to interpret.
This article provides a comprehensive review of serum protein electrophoresis, including a discussion of how the examination is performed, what it measures, and when it is indicated. The article also provides a simple guide to result interpretation and suggestions on follow-up of abnormal results.
Electrophoresis is a method of separating proteins based on their physical properties. Serum is placed on a specific medium, and a charge is applied. The net charge (positive or negative) and the size and shape of the protein commonly are used in differentiating various serum proteins. (1)
Several subsets of serum protein electrophoresis are available. The names of these subsets are based on the method that is used to separate and differentiate the various serum components. In zone electrophoresis, for example, different protein subtypes are placed in separate physical locations on a gel made from agar, cellulose, or other plant material. (2,3) The proteins are stained, and their densities are calculated electronically to provide graphical data on the absolute and relative amounts of the various proteins. Further separation of protein subtypes is achieved by staining with an immunologically active agent, which results in immunofluorescence and immunofixation.
Components of Serum Protein Electrophoresis
The pattern of serum protein electrophoresis results depends on the fractions of two major types of protein: albumin and globulins. Albumin, the major protein component of serum, is produced by the liver under normal physiologic conditions. Globulins comprise a much smaller fraction of the total serum protein content. The subsets of these proteins and their relative quantity are the primary focus of the interpretation of serum protein electrophoresis. (1,3)
Albumin, the largest peak, lies closest to the positive electrode. The next five components (globulins) are labeled [alpha.sub.1], [alpha.sub.2], [beta.sub.1], [beta.sub.2], and gamma. The peaks for these components lie toward the negative electrode, with the gamma peak being closest to that electrode. Figure 1 shows a typical normal pattern for the distribution of proteins as determined by serum protein electrophoresis.
[FIGURE 1 OMITTED]
The albumin band represents the largest protein component of human serum. The albumin level is decreased under circumstances in which there is less production of the protein by the liver or in which there is increased loss or degradation of this protein. Malnutrition, significant liver disease, renal loss (e.g., in nephrotic syndrome), hormone therapy, and pregnancy may account for a low albumin level. Burns also may result in a low albumin level. Levels of albumin are increased in patients with a relative reduction in serum water (e.g., dehydration).
Moving toward the negative portion of the gel (i.e., the negative electrode), the next peaks involve the [alpha.sub.1] and [alpha.sub.2] components. The [alpha.sub.1]-protein fraction is comprised of [alpha.sub.1]-antitrypsin, thyroid-binding globulin, and transcortin. Malignancy and acute inflammation (resulting from acute-phase reactants) can increase the [alpha.sub.1]-protein band. A decreased [alpha.sub.1]-protein band may occur because of [alpha.sub.1]-anti-trypsin deficiency or decreased production of the globulin as a result of liver disease. Ceruloplasmin, [alpha.sub.2]-macroglobulin, and haptoglobin contribute to the [alpha.sub.2]-protein band. The [alpha.sub.2] component is increased as an acute-phase reactant.
The beta fraction has two peaks labeled [beta.sub.1] and [beta.sub.2]. [Beta.sub.1] is composed mostly of transferrin, and [beta.sub.2] contains beta-lipoprotein. IgA, IgM, and sometimes IgG, along with complement proteins, also can be identified in the beta fraction.
Much of the clinical interest is focused on the gamma region of the serum protein spectrum because immunoglobulins migrate to this region. It should be noted that immunoglobulins often can be found throughout the electrophoretic spectrum. C-reactive protein (CRP) is located in the area between the beta and gamma components. (1)
Serum protein electrophoresis commonly is performed when multiple myeloma is suspected. The examination also should be considered in other “red flag” situations (Table 1). (2-4)
If the examination is normal but multiple myeloma, Waldenstrom’s macroglobulinemia, primary amyloidosis, or a related disorder still is suspected, immunofixation also should be performed because this technique may be more sensitive in identifying a small monoclonal (M) protein. (5)
Interpretation of Results
Plasma protein levels display reasonably predictable changes in response to acute inflammation, malignancy, trauma, necrosis, infarction, burns, and chemical injury. This so-called “acute-reaction protein pattern” involves increases in fibrinogen, [alpha.sub.1]-anti-trypsin, haptoglobin, cerulo-plasmin, CRP, the C3 portion of complement, and [alpha.sub.1]-acid glycoprotein. Often, there are associated decreases in the albumin and transferrin levels. (6) Table 2 (6) lists characteristic patterns of acute-reaction proteins found on serum protein electrophoresis, along with associated conditions or disorders.
In the interpretation of serum protein electrophoresis, most attention focuses on the gamma region, which is composed predominantly of antibodies of the IgG type. The gamma-globulin zone is decreased in hypo-gammaglobulinemia and agammaglobulinemia. Diseases that produce an increase in the gamma-globulin level include Hodgkin’s disease, malignant lymphoma, chronic lymphocytic leukemia, granulomatous diseases, connective tissue diseases, liver diseases, multiple myeloma, Waldenstrom’s macro-globulinemia, and amyloidosis. (3,7)
Although many conditions can cause an increase in the gamma region, several disease states cause a homogeneous spike-like peak in a focal region of the gamma-globulin zone (Figure 2). These so-called “monoclonal gammopathies” constitute a group of disorders that are characterized by proliferation of a single clone of plasma cells that produce a homogeneous M protein. (6)
[FIGURE 2 OMITTED]
Monoclonal Versus Polyclonal Gammopathies
It is extremely important to differentiate monoclonal from polyclonal gammopathies. Monoclonal gammopathies are associated with a clonal process that is malignant or potentially malignant. In contrast, polyclonal gammopathies may be caused by any reactive or inflammatory process, and they usually are associated with nonmalignant conditions. The most common conditions in the differential diagnosis of polyclonal gammopathy are listed in Table 3. (8,9)
An M protein is characterized by the presence of a sharp, well-defined band with a single heavy chain and a similar band with a kappa or lambda light chain. A polyclonal gammopathy is characterized by a broad diffuse band with one or more heavy chains and kappa and lambda light chains. (7)
Once a monoclonal gammopathy is identified by serum protein electrophoresis, multiple myeloma must be differentiated from other causes of this type of gammopathy. Among these other causes are Waldenstrom’s macroglobulinemia, solitary plasmacytoma, smoldering multiple myeloma, monoclonal gammopathy of undetermined significance, plasma cell leukemia, heavy chain disease, and amyloidosis. (4,7)
The quantity of M protein can help differentiate multiple myeloma from monoclonal gammopathy of undetermined significance. Definitive diagnosis of multiple myeloma requires 10 to 15 percent plasma cell involvement as determined by bone marrow biopsy. Characteristic differentiating features of the monoclonal gammopathies are listed in Table 4. (7)
In some patients with a plasma cell dyscrasia, serum protein electrophoresis may be normal because the complete monoclonal immunoglobulin is absent or is present at a very low level. (7) In one series, (6) serum protein electrophoresis showed a spike or localized band in only 82 percent of patients with multiple myeloma. The remainder had hypogammaglobulinemia or a normal-appearing pattern. Consequently, urine protein electrophoresis is recommended in all patients suspected of having a plasma cell dyscrasia. (10)
An additional point to consider is the size of the M-protein spike. Although this spike is usually greater than 3 g per dL in patients with multiple myeloma, up to one fifth of patients with this tumor may have an M-protein spike of less than 1 g per dL. (10) Hypogammaglobulinemia on serum protein electrophoresis occurs in about 10 percent of patients with multiple myeloma who do not have a serum M-protein spike. (11) Most of these patients have a large amount of Bence Jones protein (monoclonal free kappa or lambda chain) in their urine. (11) Thus, the size of the M-protein spike is not helpful in excluding multiple myeloma.
If multiple myeloma still is considered clinically in a patient who does not have an M-protein spike on serum protein electrophoresis, urine protein electrophoresis should be performed.
Evaluation of an Abnormal Serum Protein Electrophoresis
Monoclonal gammopathy is present in up to 8 percent of healthy geriatric patients. (12) All patients with monoclonal gammopathy require further evaluation to determine the cause of the abnormality. Patients with monoclonal gammopathy of undetermined significance require close follow-up because about 1 percent per year develop multiple myeloma or another malignant monoclonal gammopathy. (13) [Evidence level B, prospective cohort study] An algorithm for the follow-up of patients with a monoclonal gammopathy is provided in Figure 3. (6)
[FIGURE 3 OMITTED]
If the serum M-protein spike is 1.5 to 2.5 g per dL, it is important to perform nephelometry to quantify the immunoglobulins present and to obtain a 24-hour urine collection for electrophoresis and immunofixation. If these examinations are normal, serum protein electrophoresis should be repeated in three to six months; if that examination is normal, serum protein electrophoresis should be repeated annually. If the repeat examination is abnormal or future patterns are abnormal, the next step is to refer the patient to a hematologist-oncologist.
An M-protein spike of greater than 2.5 g per dL should be assessed with a metastatic bone survey that includes a single view of the humeri and femurs. In addition, a [beta.sub.2] microglobulin test, a CRP test, and a 24-hour urine collection for electrophoresis and immunofixation should be performed. If Waldenstrom’s macroglobulinemia or other lymphoproliferative process is suspected, an abdominal computed tomographic scan and bone marrow aspiration and biopsy should be performed. Abnormalities in any of these tests should result in a referral to a hematologist-oncologist. If all tests are normal, the pattern of follow-up in Figure 3 (6) can be undertaken. If serum protein electrophoresis is abnormal at any time during the follow-up, a referral should be made
Indications for Serum Protein Electrophoresis
Suspected multiple myeloma, Waldenstrom’s macroglobulinemia,
primary amyloidosis, or related disorder
Unexplained peripheral neuropathy (not attributed to longstanding
diabetes mellitus, toxin exposure, chemotherapy, etc.)
New-onset anemia associated with renal failure or insufficiency
and bone pain
Back pain in which multiple myeloma is suspected
Hypercalcemia attributed to possible malignancy (e.g., associated
weight loss, fatigue, bone pain, abnormal bleeding)
Rouleaux formations noted on peripheral blood smear
Renal insufficiency with associated serum protein elevation
Unexplained pathologic fracture or lytic lesion identified on
Bence Jones proteinuria
Information from references 2 through 4.
Characteristic Patterns of Acute-Reaction Proteins Found on
Serum Protein Electrophoresis and Associated Conditions or Disorders
Increased albumin Increased [beta.sub.1] or
Dehydration [beta.sub.2] globulins
Decreased albumin Carcinoma (sometimes)
Chronic cachectic or wasting Cushing’s disease
diseases Diabetes mellitus (some cases)
Chronic infections Hypothyroidism
Hemorrhage, burns, or Iron deficiency anemia
protein-losing enteropathies Malignant hypertension
Impaired liver function Nephrosis
resulting from decreased Polyarteritis nodosa
synthesis of albumin Obstructive jaundice
Malnutrition Third-trimester pregnancy
Pregnancy Decreased [beta.sub.1] or
Increased [alpha.sub.1] Protein malnutrition
Pregnancy Increased gamma globulins
Decreased [alpha.sub.1] Chronic infections (granulomatous
globulins diseases)[Alpha.sub.1]-antitrypsin Chronic lymphocytic leukemia
Increased [alpha.sub.2] Malignant lymphoma
globulins Multiple myeloma
Adrenal insufficiency Rheumatoid and collagen diseases
Adrenocorticosteroid theraphy (connective tissue disorders)
Advanced diabetes mellitus Waldenstrom’s macroglobulinemia
Decreased gamma globulins
Decreased [alpha.sub.2] Agammaglobulinemia
Severe liver disease
Information from reference 6.
Differential Diagnosis of Polyclonal Gammopathy
Viral infections, especially Solid tumors
hepatitis, human Ovarian tumors
immunodeficiency virus Lung cancer
infection, mononucleosis, Hepatocellular cancer
and varicella Renal tumors
Focal or systemic bacterial Gastric tumors
infections, including Hematologic cancers (see below)
and bacteremia Hematologic and lymphoproliferative
Connective tissue diseases Leukemia
Systemic lupus er ythematosus Thalassemia
Mixed connective tissue Sickle cell anemia
Rheumatoid arthritis Other inflammatory conditions
Sarcoid Gastrointestinal conditions,
Liver diseases colitis and Crohn’s disease
Cirrhosis Pulmonary disorders, including
Ethanol abuse bronchiectasis, cystic fibrosis,
Autoimmune hepatitis chronic bronchitis, and
Viral-induced hepatitis pneumonitis
Primary biliary cirrhosis Endocrine diseases, including
Primary sclerosing cholangitis Graves’ disease and Hashimoto’s
Information from references 8 and 9.
Characteristic Features of Monoclonal Gammopathies
Disease Distinctive features
Multiple myeloma M protein appears as a narrow spike in the gamma,
beta, or [alpha.sub.2] regions.
M-protein level is usually greater than 3 g per dL.
Skeletal lesions (e.g., lytic lesions, diffuse
osteopenia, vertebral compression fractures) are
present in 80 percent of patients.
Diagnosis requires 10 to 15 percent plasma cell
involvement on bone marrow biopsy.
Anemia, pancytopenia, hypercalcemia, and renal
disease may be present.
Monoclonal M-protein level is less than 3 g per dL.
gammopathy of There is less than 10 percent plasma cell
undetermined involvement on bone marrow biopsy.
significance Affected patients have no M protein in their urine,
no lytic bone lesions, no anemia, no
hypercalcemia, and no renal disease.
Smoldering M-protein level is greater than 3 g per dL.
multiple myeloma There is greater than 10 percent plasma cell
involvement on bone marrow biopsy.
Affected patients have no lytic bone lesions,
no anemia, no hypercalcemia, and no renal
Plasma cell Peripheral blood contains more than 20 percent
leukemia plasma cells.
M-protein levels are low.
Affected patients have few bone lesions and few
This monoclonal gammopathy occurs in younger
Solitary Affected patients have only one tumor, with no
plasmacytoma other bone lesions and no urine or serum
Waldenstrom’s IgM M protein is present.
macro- Affected patients have hyper viscosity and
globulinemia hypercellular bone marrow with extensive
infiltration by lymphoplasma cells.
Heavy chain The M protein has an incomplete heavy chain and no
disease light chain.
Adapted with permission from George ED, Sadovsky R. Multiple myeloma:
recognition and management. Am Fam Physician 1999;59:1889.
(1.) Jacoby RF, Cole CE. Molecular diagnostic methods in cancer genetics. In: Abeloff MD, et al., eds. Clinical oncology. 2d ed. New York: Churchill Livingstone, 2000:119-21.
(2.) Hoffman R, et al., eds. Hematology: basic principles and practice. 3d ed. New York: Churchill Livingstone, 2000:369-70,1403,2505-9.
(3.) Ravel R. Clinical laboratory medicine: clinical application of laboratory data. 6th ed. St. Louis: Mosby, 1995:343-6,350.
(4.) Bigos SJ, et al. Acute low back problems in adults. Rockville, Md.: U.S. Dept. of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1994; clinical practice guideline no. 14, AHCPR publication no. 95-0642.
(5.) Kyle RA. The monoclonal gammopathies. Clin Chem 1994;40(11 pt 2):2154-61.
(6.) Kyle RA. Sequence of testing for monoclonal gammopathies. Arch Pathol Lab Med 1999;123:114-8.
(7.) George ED, Sadovsky R. Multiple myeloma: recognition and management. Am Fam Physician 1999;59:1885-94.
(8.) Dispenzieri A, Gertz MA, Therneau TM, Kyle RA. Retrospective cohort study of 148 patients with polyclonal gammopathy. Mayo Clin Proc 2001;76:476-87.
(9.) Wallach JB. Interpretation of diagnostic tests. 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2000:78-83.
(10.) Alexanian R, Weber D, Liu F. Differential diagnosis of monoclonal gammopathies. Arch Pathol Lab Med 1999;123:108-13.
(11.) Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proc 2003;78:21-33.
(12.) Boccadoro M, Pileri A. Diagnosis, prognosis, and standard treatment of multiple myeloma. Hematol Oncol Clin North Am 1997;11:111-31.
(13.) Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:564-9.
THEODORE X. O’CONNELL, M.D., is associate program director and director of the research curriculum at the Kaiser Permanente Woodland Hills (Calif.) Family Medicine Residency Program. He also is clinical instructor in the Department of Family Medicine at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). Dr. O’Connell is a partner physician with Southern California Permanente Medical Group, Woodland Hills. He received his medical degree from UCLA School of Medicine and completed a family medicine residency and chief residency at Santa Monica-UCLA Medical Center.
TIMOTHY J. HORITA, M.D., is program director at the Kaiser Permanente Woodland Hills Family Medicine Residency Program and clinical assistant professor in the Department of Family Medicine at the David Geffen School of Medicine at UCLA. He is a partner physician with Southern California Permanente Medical Group. Dr. Horita received his medical degree from Dartmouth Medical School, Hanover, N.H., and completed a family medicine residency and chief residency at Kaiser Permanente Medical Center, Woodland Hills.
BARSAM KASRAVI, M.D., is currently pursuing a master’s degree in public health administration at Harvard University, Boston. Dr. Kasravi received his medical degree from the UCLA School of Medicine and completed a residency at the Kaiser Permanente Woodland Hills Family Medicine Residency Program where he was chief resident.
Address correspondence to Theodore X. O’Connell, M.D., Kaiser Permanente Woodland Hills Family Medicine Residency Program, 5601 DeSoto Ave., Woodland Hills, CA 91365. Reprints are not available from the authors.
The authors indicate that they do not have any conflicts of interest. Sources of funding: none reported.
The author thanks Elliott Gordon, librarian at Kaiser Permanente Medical Center, Woodland Hills, Calif., for his assistance with literature searches.
COPYRIGHT 2005 American Academy of Family Physicians
COPYRIGHT 2005 Gale Group